Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)

Description

The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.

Conditions

Delirium, Delirium in Old Age, Critical Illness, Intensive Care Unit Delirium

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)

Condition
Delirium
Intervention / Treatment

-

Contacts and Locations

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Mechanically ventilated patients aged \>=50 years
  • * RASS score of -3 to +1 and
  • * Anticipated to require \>=24 hours of mechanical ventilation
  • * Not expected to survive \>=24 hours
  • * Have limitations in care (Do Not Resuscitate, or comfort-focused care orders)
  • * Receiving paralytic neuromuscular blocking agent (NMBA) infusion or anticipated need for NMBA use
  • * Have advanced dementia or cognitive impairment including post-concussive syndrome.
  • * Have acute or subacute neurological disorders.
  • * Have severe uncorrected psychiatric disorders.
  • * Have uncorrected hearing or visual impairment.
  • * Acute or subacute neurological disorder hindering communication or ability to participate in CAM ICU assessments
  • * Enrolled in a clinical trial which prohibits co-enrollment.
  • * Incarcerated
  • * Have no identified legally appointed representative (LAR)
  • * Are unable to communicate in the predominant local language (English at US site and English/Hebrew/Arabic/Russian in Israel)
  • * Refusal of treating clinical team.

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Beth Israel Deaconess Medical Center,

Somnath Bose, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center

Study Record Dates

2025-05-31